Non-Hodgkin Lymphoma

Capital investment to be used in part for cancer vaccine development

Published in Cancer Weekly, November 11th, 2003

Biovest International announced the completion of $5 million of capital investment under its April 10, 2003, investment agreement with Accentia, Inc., a Hopkins Capital Group portfolio company.

The recently received capital represents the initial tranche of a multi-year, $20 million investment commitment.

Biovest, which is designated the National Cell Culture Center by the National Institutes of Health, is utilizing a portion of this investment to expand its core businesses of contract biologic production and the manufacture and sale of proprietary cell culture production equipment.

Additionally, a portion of the invested capital...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry